TriSalus Q3 revenue $5.2M (+32% YoY); net loss $1.7M; PERIO-01 median PFS 11.7 months

TriSalus Life Sciences, Inc.

2023-Q3 EPS reported -$5.68 revenue$12,790,000

Q3 revenue $5.2M, up 32% YoY; nine-month revenue $12.8M, up 39% YoY; gross margin 89%.
Operating loss $18.5M (incl. $4.8M deSPAC costs); net loss $1.7M; diluted EPS loss $0.13.
PERIO-01 Phase 1 data: median PFS 11.7 months, DCR 81%, 1-year OS 86%.
PERIO-03 initial safety/feasibility for pancreatic cancer; dose expansion with anti-PD-1 expected early 2024.
Appointed Jodi Devlin as President, Commercial Operations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TriSalus Life Sciences, Inc. reported the three and nine month periods ended September 30, 2023 results: revenue $5.2 million, net income $1.7 million and $27.0 million, respectively, for the third quarter and nine months ended September 30, 2023, EPS Basic and diluted loss per share for the three and nine months ended September 30, 2023, was $0.

Period: the three and nine month periods ended September 30, 2023
Revenue: $5.2 million
Net income: $1.7 million and $27.0 million, respectively, for the third quarter and nine months ended September 30, 2023
EPS: Basic and diluted loss per share for the three and nine months ended September 30, 2023, was $0
Result: reported results

Exact text from the filing

Financial Results and Provides Business Update Completed merger with MedTech Acquisition Corporation (MTAC) and started public trading August 11 th Reported 3Q23 revenues of $5.2 million in 3Q23, up 32% over prior year and nine-month year to date net revenues of $12.8 million, up 39% over prior year Favorable Phase 1 uveal melanoma PERIO-01 data demonstrating

View on SEC.gov

50 earnings releases filed in the last 30 days. Browse all earnings releases →

TriSalus Life Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-117720

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.